Warning on a common Rx drug

By the Editorial Team · Thursday, September 17, 2026

A global analysis of over 22,000 patients found that the antibiotic cefepime is associated with a higher risk of all-cause mortality compared to other beta-lactam antibiotics. This raises concerns about its safety and highlights the need for careful patient assessment and consideration of alternative treatments, particularly for vulnerable populations.

A recent global analysis has raised concerns about the safety of cefepime, a widely used antibiotic prescribed for bacterial infections such as pneumonia, urinary tract infections, and skin infections. The study linked the drug to an increased risk of all-cause mortality.

Cefepime, typically administered by injection in clinical settings, is favored for its broad-spectrum activity against various infections. However, prior reports have highlighted severe neurological side effects in some patients, particularly older adults, including confusion, decreased consciousness, and seizures, as noted by Mayo Clinic.

The new research examined data from 110 randomized clinical trials, encompassing over 22,000 patients who received either cefepime or antibiotics from a related class that includes penicillins. The investigators aimed to assess the overall safety profile of cefepime relative to these alternatives.

Findings from the analysis indicated a statistically significant increase in the risk of death among patients treated with cefepime compared to those receiving other beta-lactam antibiotics. While the exact mechanisms behind this association remain unclear, the researchers emphasized the importance of weighing potential benefits against risks when selecting antibiotic therapy, especially for vulnerable populations.

Medical experts caution that while cefepime remains an important option for treating serious bacterial infections, clinicians should remain vigilant for adverse effects and consider individual patient risk factors. Additional studies are needed to further clarify the drug’s safety and to guide optimal usage.

The study’s authors and healthcare providers recommend heightened surveillance for neurological symptoms during treatment and suggest that alternative antibiotics may be preferable in some cases. The findings underscore the ongoing need to review and update prescribing practices based on emerging evidence to ensure patient safety.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.